ZHAOKE OPHTH-B(06622.HK): Australia's TGA Accepts Registration Application for 0.02% Atropine Sulfate Eye Drops
NewTimeSpace News: Zhaoke Ophthalmology Limited (06622.HK) announced that the Therapeutic Goods Administration (TGA) of Australia has accepted for review the registration application for its 0.02% Atropine Sulfate Eye Drops (Product Code: NVK002), a treatment for slowing the progression of myopia in children. The application is supported by results from the Company's Phase III clinical trials.
NewTimeSpace News: Zhaoke Ophthalmology Limited (06622.HK) released a voluntary announcement on June 15, 2026. On June 2, 2026, Australia's Therapeutic Goods Administration accepted and commenced the review of the registration application for the Company's 0.02% Atropine Sulfate Eye Drops (Product Code: NVK002), which is indicated for slowing the progression of myopia in children. The TGA formally notified the Company that the application has passed the preliminary assessment and will undergo further review.
As a patented formulation, NVK002 is an eye drop designed to slow the progression of myopia in children and adolescents. It effectively addresses the instability of low-concentration atropine and contains no preservatives, with an expected shelf life of 24 months.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
Tags：
